No differences in intervention effects depending on NAFLD at baseline were observed regarding parameters of glucose metabolism (fasting glucose, HbA1c), lipid metabolism (HDL, LDL), adipokine signaling (leptin, resistin) or inflammation (CRP). The gene discussed is LEP; the disease is metabolic dysfunction-associated steatotic liver disease.